> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# ClearPoint Neuro Revenue Jumps 36% To $12.1 Million On IRRAflow, But Net Loss Widens To $7.5 Million
- URL: https://www.bullished.co/clearpoint-neuro-revenue-jumps-36-to-12-1-million-on-irraflow-but-net-loss-widens-to-7-5-83027406/
- Published: 2026-10-28T20:11:45.000Z
- Updated: 2026-10-28T20:11:45.000Z
- Description: The brain-surgery device maker now estimates 2026 revenue of $48.0 million to $50.0 million and ended September with $46.2 million in cash.
- Author: Matteo Parrino
- Tags: Earnings, CLPT, Industry: Healthcare

ClearPoint Neuro, which makes systems for minimally invasive brain surgery, said third-quarter [revenue rose 36% to $12.1 million](https://www.sec.gov/Archives/edgar/data/0001285550/000119312526436125/clpt-ex99%5F1.htm?ref=bullished.co) from $8.9 million a year earlier, lifted by the IRRAflow line it bought with IRRAS. The net loss widened to $7.5 million, or $0.24 per share, from $5.9 million, or $0.21, in an [8-K filed](https://www.sec.gov/Archives/edgar/data/0001285550/000119312526436125/clpt-20261028.htm?ref=bullished.co) Wednesday.

## Where the growth came from

Neurosurgery navigation and therapy revenue, mostly disposables used in cases with the ClearPoint and IRRAflow systems, rose 59% to $5.4 million from $3.4 million. The company said the gain came mainly from IRRAflow sales; it bought IRRAS in the fourth quarter of 2025.

Capital equipment and software revenue climbed 68% to $1.7 million from $1.0 million, which the company called a record. Biologics and drug delivery revenue rose 11% to $4.9 million from $4.4 million, mostly from services at ClearPoint Advanced Laboratories.

The company also said one partner submitted the first formal biologics license application, an FDA approval filing, for a Huntington's disease treatment.

## Margins thin as costs climb

Gross margin slipped to 58% from 63%, which the company blamed on overhead at the new ClearPoint Advanced Laboratories facility and extra amortization of acquired intangibles. Operating expenses rose 23% to $13.4 million from $10.9 million, mainly from the IRRAS deal: more clinical and sales staff, plus higher occupancy and travel costs.

CEO Joe Burnett said revenue growth of 36% outpaced expense growth of 23%, as finishing the IRRAflow integration "has enabled improved operating leverage." Interest expense for the quarter was $1.4 million, up from $0.9 million.

## Cash, guidance and the stock sales

Cash and equivalents stood at $46.2 million at September 30, against $45.9 million at December 31, 2025\. Net proceeds of $22.0 million from the company's at-the-market stock offering program were largely offset by $20.1 million used in operations over the first nine months of 2026.

The company now estimates 2026 revenue of $48.0 million to $50.0 million. Its investor presentation shows 2025 revenue of $37.0 million.

Management discussed the results on a call at 4:30 p.m. Eastern Wednesday. A replay runs until November 27.

Over the first nine months, revenue reached $35.1 million against $26.6 million a year earlier, while the net loss grew to $28.3 million from $17.8 million.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — ClearPoint Neuro, Inc. (CLPT)](https://www.sec.gov/Archives/edgar/data/0001285550/000119312526436125/clpt-20261028.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit clpt-ex99\_1.htm — ClearPoint Neuro, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001285550/000119312526436125/clpt-ex99%5F1.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit clpt-ex99\_2.htm — ClearPoint Neuro, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001285550/000119312526436125/clpt-ex99%5F2.htm?ref=bullished.co) — SEC EDGAR
- [ClearPoint Neuro to Announce Third Quarter 2026 Results October 28, 2026 - The Globe and Mail](https://www.theglobeandmail.com/investing/markets/markets-news/ACCESS%20Newswire/7700789/clearpoint-neuro-to-announce-third-quarter-2026-results-october-28-2026/?ref=bullished.co) — theglobeandmail.com